DE BRAUD, FILIPPO GUGLIELMO MARIA
DE BRAUD, FILIPPO GUGLIELMO MARIA
Dipartimento di Oncologia ed Emato-Oncologia
"Burned out" phenomenon of the testis in retroperitoneal seminoma
2006 G. Curigliano , E. Magni , G. Renne , O. De Cobelli , M. Rescigno , R. Torrisi , G. Spitaleri , E. Pietri , F. De Braud , A. Goldhirsch
18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy : a pilot study
2015 F. Crippa, R. Agresti, M. Sandri, G. Mariani, B. Padovano, A. Alessi, G. Bianchi, E. Bombardieri, I. Maugeri, M. Rampa, M.L. Carcangiu, G. Trecate, C. Pascali, A. Bogni, G. Martelli, F. de Braud
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
2018 F. Toffalorio, M. Santarpia, D. Radice, C. Jaramillo, G. Spitaleri, M. Manzotti, C. Catania, L. Jordheim, G. Pelosi, G. Peters, C. Tibaldi, N. Funel, L. Spaggiari, F. de Braud, T. De Pas, E. Giovannetti
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
2004 A. Roth, R. Maibach, N. Fazio, C. Sessa, R. Stupp, R. Morant, R. Herrmann, M. Borner, A. Goldhirsch, F. de Braud
A 15-min premedication for 1-h paclitaxel infusion: optimizing patients' care
2007 A. Milani, T. De Pas, C. Noberasco, C. Mcdonnell, L. Libutti, I. Limardi, C. Zencovich, S. Boselli, M. Bianchi, F. de Braud
A catalyst for change: The european cancer patient's bill of rights
2014 M. Lawler, T. Le Chevalier, M. J. Murphy J. r., I. Banks, P. Conte, F. De Lorenzo, F. Meunier, H.M. Pinedo, P. Selby, J. Armand, M. Barbacid, M. Barzach, J. Bergh, G. Bode, D.A. Cameron, F. de Braud, A. de Gramont, V. Diehl, S. Diler, S. Erdem, J.M. Fitzpatrick, J. Geissler, D. Hollywoodz, L. Højgaard, D. Horgan, J. Jassem, P.W. Johnson, P. Kapitein, J. Kellyv, S. Kloezen, C. La Vecchia, B. Löwenberg, K. Oliver, R. Sullivan, J. Tabernero, C.J. van de Velde, N. Wilking, R. Wilson, C. Zielinski, H. zur Hausen, P.G. Johnston
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
2018 S. Pusceddu, F. Barretta, A. Trama, L. Botta, M. Milione, R. Buzzoni, F. De Braud, V. Mazzaferro, U. Pastorino, E. Seregni, L. Mariani, G. Gatta, M. Di Bartolomeo, D. Femia, N. Prinzi, J. Coppa, F. Panzuto, L. Antonuzzo, E. Bajetta, M. Pia Brizzi, D. Campana, L. Catena, H. Comber, F. Dwane, N. Fazio, A. Faggiano, D. Giuffrida, K. Henau, T. Ibrahim, R. Marconcini, S. Massironi, M.P. Zakelj, F. Spada, S. Tafuto, E. Van Eycken, J.M. Van Der Zwan, T. Zagar, L. Giacomelli, R. Miceli
A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis
2021 M. Lecchi, P. Verderio, V. Cappelletti, F. De Santis, B. Paolini, M. Monica, S. Sangaletti, S.M. Pupa, M.V. Iorio, G. Bianchi, M. Gennaro, G. Fuca, F. De Braud, E. Tagliabue, M. Di Nicola
A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer
2010 T. De Pas, S. Raimondi, G. Pelosi, L. Spaggiari, F. De Braud, G. Veronesi, P. Maisonneuve
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
2011 T. Eigentler, B. Weide, F. de Braud, G. Spitaleri, A. Romanini, A. Pflugfelder, R. González-Iglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. Trachsel, H. Menssen, D. Neri, C. Garbe
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
2013 E. Gallerani, M. Zucchetti, D. Brunelli, E. Marangon, C. Noberasco, D. Hess, A. Delmonte, G. Martinelli, S. Böhm, C. Driessen, F. De Braud, S. Marsoni, R. Cereda, F. Sala, M. D'Incalci, C. Sessa
A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma
2010 C. Catania, G. Pelosi, N. Fazio, R. Biffi, G. Spitaleri, C. Noberasco, M.G. Zampino, A. Maggioni, G. Trifirò, F. Toffalorio, P.D. Vigna, F. De Braud, T. De Pas
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
2015 M. Dugo, G. Nicolini, G. Tragni, I. Bersani, A. Tomassetti, V. Colonna, M. Del Vecchio, F. De Braud, S. Canevari, A. Anichini, M. Sensi
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
2015 F. Pietrantonio, G. Aprile, L. Rimassa, P. Franco, S. Lonardi, C. Cremolini, P. Biondani, E.L. Sbicego, F. Pasqualetti, G. Tomasello, M. Niger, M. Casagrande, M. Ghidini, R. Muni, S. Montrone, F. Bergamo, R. Berenato, C. Fontanella, S. Bozzarelli, R. Moretto, F. Battaglin, M. Di Bartolomeo, F. De Braud, R. Miceli
A Phase I dose-escalation study with weekly taxol and gemcitabine in patients with advanced non small cell lung cancer
1998 T. De Pas, F. de Braud, C. Sessa, A. Sbanotto, C. Catania, G. Zampino, I. Minchella, S. Cinieri, M. Colleoni, F. Nolè, S. Ghilenzan, E.A.G. Marrocco
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
2016 L.W. Goff, R.B. Cohen, J.D. Berlin, F.G. De Braud, A. Lyshchik, C. Noberasco, F. Bertolini, M. Carpentieri, C.G. Stampino, A. Abbattista, E. Wang, H. Borghaei
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor,brivanib, in patients with advanced or metastatic solid tumors
2011 D. Jonker, L. Rosen, M. Sawyer, F. de Braud, G. Wilding, C. Sweeney, G. Jayson, G. Mcarthur, G. Rustin, G. Goss, J. Kantor, L. Velasquez, S. Syed, O. Mokliatchouk, D. Feltquate, G. Kollia, D. Nuyten, S. Galbraith
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
2015 F. de Braud, S. Cascinu, G. Spitaleri, K. Pilz, L. Clementi, D. Liu, P. Sikken, T. De Pas
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients
2006 T. De Pas, C. Putzu, G. Curigliano, C. Noberasco, S. Boselli, C. Catania, L. Orlando, A. Milani, L. Spaggiari, F. de Braud
A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients
2001 R. Biffi, F. De Braud, F. Orsi, S. Pozzi, P. Arnaldi, A. Goldhirsch, N. Rotmensz, C. Robertson, M. Bellomi, B. Andreoni